当前位置: 首页 > 期刊 > 《中国医药导报》 > 2017年第3期
编号:1597399
GATA3在前列腺癌组织中的表达及临床意义
http://www.100md.com 2017年3月21日 中国医药导报 2017年第3期
良性前列腺增生,免疫组化
     钗丽干 张帆

    [摘要] 目的 探讨GATA3在前列腺癌(PCa)组织中的表达并分析其与临床病理特征的关系。 方法 选取2013年3月~2015年12月内蒙古自治区人民医院病理科存档的92例PCa穿刺活检患者标本为PCa组及患者年龄相匹配的60例良性前列腺增生(BPH)蜡块为BPH组,采用免疫组化法检测两组中GATA3的表达情况。 结果 PCa组中GATA3的阳性表达率为83.70%,BPH组中GATA3阳性表达率为10.00%,差异有统计学意义(P 0.05)。 结论 GATA3在PCa中高表达,提示其参与PCa的发展进程。

    [关键词] 前列腺癌;良性前列腺增生;GATA3;免疫组化

    [中图分类号] R737.25 [文献标识码] A [文章编号] 1673-7210(2017)01(c)-0023-04

    [Abstract] Objective To investigate the expression of GATA3 in prostate cancer (PCa) and its correlation with clinico-pathologic parameters. Methods 92 cases of PCa biopsy specimens in Department of Pathology, Inner Mongolia People′s Hospital from March 2013 to December 2015 were selected as PCa group, 60 wax blocks of BPH with age matched were selected as BPH group. Immunohistochemical method was used to detect the expression of GATA3 in two groups. Results The positive expression rate of GATA3 in PCa group was 83.70%, positive expression rate of GATA3 in BPH group was 10.00%, with statistical difference (P < 0.05). The positive expression rate of GATA3 in PCa patients was positively related to the development of Gleason score ......

您现在查看是摘要页,全文长 10285 字符